alexa Commentary on Bevacizumab in Ovarian Cancer: Focus on Clinical Data andFuture Perspectives | OMICS International | Abstract

Insights in Gynecologic Oncology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Commentary on Bevacizumab in Ovarian Cancer: Focus on Clinical Data andFuture Perspectives

Vanda Salutari*, Giovanni Scambia

Gynecology Oncology Unit, Policlinico Universitario Agostino Gemelli, Rome, Italy

*Corresponding Author:
Vanda Salutar
Gynecology Oncology Unit
Policlinico Universitario Agostino Gemelli
Rome, Italy
Tel: +39 06 3551 0330
E-mail: [email protected]

Received Date: January 30, 2016; Accepted Date: February 19, 2016; Published Date: February 26, 2016

Citation: Salutari V, Scambia G (2016) Commentary on Bevacizumab in Ovarian Cancer: Focus on Clinical Data and Future Perspectives. Trends Gynecol Oncol 1:103. doi:10.4172/CTGO.1000103

Copyright: © 2016 Salutari V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top